» Articles » PMID: 27899802

Genomic and Transcriptional Landscape of P2RY8-CRLF2-positive Childhood Acute Lymphoblastic Leukemia

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2016 Dec 1
PMID 27899802
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Children with P2RY8-CRLF2-positive acute lymphoblastic leukemia have an increased relapse risk. Their mutational and transcriptional landscape, as well as the respective patterns at relapse remain largely elusive. We, therefore, performed an integrated analysis of whole-exome and RNA sequencing in 41 major clone fusion-positive cases including 19 matched diagnosis/relapse pairs. We detected a variety of frequently subclonal and highly instable JAK/STAT but also RTK/Ras pathway-activating mutations in 76% of cases at diagnosis and virtually all relapses. Unlike P2RY8-CRLF2 that was lost in 32% of relapses, all other genomic alterations affecting lymphoid development (58%) and cell cycle (39%) remained stable. Only IKZF1 alterations predominated in relapsing cases (P=0.001) and increased from initially 36 to 58% in matched cases. IKZF1's critical role is further corroborated by its specific transcriptional signature comprising stem cell features with signs of impaired lymphoid differentiation, enhanced focal adhesion, activated hypoxia pathway, deregulated cell cycle and increased drug resistance. Our findings support the notion that P2RY8-CRLF2 is dispensable for relapse development and instead highlight the prominent rank of IKZF1 for relapse development by mediating self-renewal and homing to the bone marrow niche. Consequently, reverting aberrant IKAROS signaling or its disparate programs emerges as an attractive potential treatment option in these leukemias.

Citing Articles

Non-histone lactylation: unveiling its functional significance.

Shi P, Ma Y, Zhang S Front Cell Dev Biol. 2025; 13:1535611.

PMID: 39925738 PMC: 11802821. DOI: 10.3389/fcell.2025.1535611.


Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia.

Hormann F, Ostergaard A, van den Broek S, Boeree A, van de Ven C, Escherich G Hemasphere. 2025; 9(1):e70069.

PMID: 39840380 PMC: 11746935. DOI: 10.1002/hem3.70069.


Philadelphia chromosome-like acute lymphoblastic leukemia with concomitant rearrangements of CRLF2 and ABL1: a pediatric case report.

He G, Lei Y, Huang D, Gao J, Yang R BMC Pediatr. 2024; 24(1):517.

PMID: 39127642 PMC: 11316372. DOI: 10.1186/s12887-024-04991-w.


Advances in next-generation sequencing for relapsed pediatric acute lymphoblastic leukemia: current insights and future directions.

Mohd Nippah N, Abu N, Ab Mutalib N, Alias H Front Genet. 2024; 15:1394523.

PMID: 38894724 PMC: 11183504. DOI: 10.3389/fgene.2024.1394523.


Comprehensive detection of alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.

Gil J, Miralles A, de Las Heras S, Such E, Avetisyan G, Diaz-Gonzalez A Front Mol Biosci. 2024; 11:1362081.

PMID: 38370004 PMC: 10869515. DOI: 10.3389/fmolb.2024.1362081.


References
1.
Roll J, Reuther G . CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res. 2010; 70(19):7347-52. PMC: 2948596. DOI: 10.1158/0008-5472.CAN-10-1528. View

2.
von Stackelberg A, Seeger K, Henze G, Eckert C . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia. 2004; 18(10):1727-8. DOI: 10.1038/sj.leu.2403475. View

3.
Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor H, te Kronnie T . Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups. Br J Haematol. 2012; 158(6):772-7. DOI: 10.1111/j.1365-2141.2012.09221.x. View

4.
Maude S, Tasian S, Vincent T, Hall J, Sheen C, Roberts K . Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012; 120(17):3510-8. PMC: 3482861. DOI: 10.1182/blood-2012-03-415448. View

5.
Xavier A, Ge Y, Taub J . Unique clinical and biological features of leukemia in Down syndrome children. Expert Rev Hematol. 2010; 3(2):175-86. DOI: 10.1586/ehm.10.14. View